<DOC>
	<DOCNO>NCT02568111</DOCNO>
	<brief_summary>The primary objective study evaluate Injection Related Erythema ( IRE ) mitigation effect single administration brimonidine tartrate comparison vehicle gel ( placebo ) . The secondary study objective evaluate IRE mitigation effect single administration brimonidine tartrate comparison vehicle gel stringent definition scale , accordance primary endpoint original brimonidine pivotal trial participant ' satisfaction overall appearance skin .</brief_summary>
	<brief_title>Brimonidine Tartrate Treatment Injection Related Erythema</brief_title>
	<detailed_description>Participants naïve treatment subcutaneous ( SC ) interferons oral Disease Modifying Therapy ( DMT ) start PLEGRIDY PEN therapy screen participation Phase IV trial . Participants remain Plegridy therapy prescribe physician . Plegridy provide participant Biogen part study .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>Key RRMS patient naïve treatment SC interferon oral and/or IV DMT PLEGRIDY deem necessary treating physician . Patient willing able complete PSA PAA questionnaires minimal assistance . Key Known allergy interferon component peginterferon beta1a . Patients hypersensitivity Brimonidine topical gel . Patients skin disorder . History previous treatment Brimonidine tartrate . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>erythema</keyword>
	<keyword>PLEGRIDY</keyword>
	<keyword>injection site reaction ( ISR )</keyword>
	<keyword>MS</keyword>
	<keyword>RRMS</keyword>
</DOC>